Why the study?
Does antiplatelet monotherapy have different efficacy and safety outcomes in Asian compared to non-Asian patients with non-cardioembolic stroke/TIA?
Does antiplatelet monotherapy have different efficacy and safety outcomes in Asian compared to non-Asian patients with non-cardioembolic stroke/TIA?
Asian patients receiving antiplatelet monotherapy for secondary prevention of non-cardioembolic stroke/TIA have a similar risk of ischemic events but a significantly higher risk of hemorrhagic events compared to non-Asian patients.
No takes yet. Share an insight, caveat, or question.
Asian patients may need closer ICH monitoring on antiplatelet monotherapy; hypothesis-generating and requires randomized confirmation before practice change.
Hoshino et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: